TB vaccines in clinical development
Open Access
- 1 August 2016
- journal article
- Published by Elsevier in Tuberculosis
- Vol. 99, S16-S20
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- T-cell activation is an immune correlate of risk in BCG vaccinated infantsNature Communications, 2016
- First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adultsVaccine, 2015
- Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic settingVaccine, 2015
- Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trialThe Lancet Respiratory Medicine, 2015
- Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosisVaccine, 2015
- Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trialThe Lancet Infectious Diseases, 2014
- The BCG replacement vaccine VPM1002: from drawing board to clinical trialExpert Review of Vaccines, 2014
- Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trialThe Lancet, 2013
- A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human VolunteersThe Journal of Infectious Diseases, 2008
- Global Forum on TB Vaccine Research and Development. World Health Organization, June 7–8 2001, GenevaTuberculosis, 2001